SINGLE AGENT CARBOPLATIN VERSUS CARBOPLATIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN IN RECURRENT OVARIAN CANCER: FINAL SURVIVAL RESULTS OF A SWOG (S0200) PHASE 3 RANDOMIZED TRIAL

OBJECTIVES: Randomized phase 3 trials have demonstrated the utility of a regimen of carboplatin plus pegylated liposomal doxorubicin (PLD) in recurrent ovarian cancer, and have provided provocative data suggesting a substantially lower risk of carboplatin-associated hypersensitivity if PDL is delive...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Markman, Maurie, Moon, James, Wilczynski, Sharon, Lopez, Ana Maria, Rowland, Kendrith M., Michelin, David P., Lanzotti, Victor J., Anderson, Garnet L., Alberts, David S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2836168/
https://ncbi.nlm.nih.gov/pubmed/20044128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2009.11.026
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados